Central Nervous System Treatment Market Size, Share, Growth Analysis, By Disease Type(Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative diseases), By Drug class(Immunomodulatory drugs, interferons, Decarboxylase Inhibitors, Dopamine Agonists), By Drug Type(Biologics, Non-Biologics), By Region - Industry Forecast 2024-2031

Central Nervous System Treatment Market Drivers

Increasing prevalence of mental diseases and pipeline researches is substantially driving the market growth.

• The frequency and incidence of neurological illnesses, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease, among others, are rapidly rising globally. In the upcoming years, the market's growth is expected to be significantly impacted by this increase. On the other side, countries with an increasing geriatric population are also experiencing an upsurge in the prevalence of Alzheimer's disease. For instance, the Alzheimer's Association estimates that more than five million people worldwide already suffer from Alzheimer's disease, and that figure is expected to increase to 14 million by the year 2050. 
• Over the course of the forecast period, market growth is predicted to be fueled by potential product launches for the treatment of neurological illnesses. It is anticipated that these planned launches would improve access to healthcare in developing nations. For instance, Lenabasum is presently undergoing a Phase 3 clinical research by Corbus Pharmaceuticals Inc. to assess its safety and effectiveness in the management of diffuse cutaneous systemic sclerosis. 

Central Nervous System Treatment Market Restraints

High cost of drug development and the regulatory hurdles to restrain the growth

• Investments in the therapeutic research and development are higher than other therapeutic illness areas. Since the therapies created for treating the central nervous system requires high accuracy, there is a limited availability of medical professionals. To develop a CNS related drug that affects brain and behaviour, the drug approval has a lengthy approval process which can take years to finalize.
• The field of neuroscience is backed by research and intense work related to understanding a particular subject in the field. However, poor or limited understanding can create diversions and limit the ability of the company to receive timely approvals and can cause delay in rolling out a vaccine to treat CNS disorders.